The Bombay High Court has directed the Maharashtra FDA to withdraw its order cancelling the license of Cipla’s Pune facility, citing procedural violations and unfair conduct. The court criticized the regulator for issuing a closure order on a public holiday without a fair hearing. While the company maintains product quality is safe, investors should monitor the upcoming fresh show cause proceedings and broader regulatory compliance risks.
The Bombay High Court intervened on Saturday in a dispute between Cipla and the Maharashtra Food and Drug Administration (FDA), directing the state regulator to withdraw an order that had cancelled the drug sale license of the company’s Wadki facility in Pune. The court bench, comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, described the FDA's actions as high-handed, noting that the agency breached basic legal principles by issuing a closure order on a public holiday without granting the company a fair opportunity to be heard.
The regulatory conflict originated from an inspection conducted in June 2026. During this review, FDA investigators raised objections regarding the packaging of 'Reactin Plus Tablets,' alleging that the labels used terms like 'analgesic' and 'antipyretic,' which the regulator argued could promote self-medication for Schedule H prescription drugs. The FDA also cited concerns related to discrepancies between physical and computerized stock records, alongside claims regarding product recall compliance. Cipla has clarified that these issues did not involve the safety, efficacy, or quality of the medicines themselves, ensuring that patient health remained protected throughout the dispute.
While the court’s intervention offers a procedural reset, the matter is not fully closed. The FDA has been tasked with issuing a fresh show cause notice to the company, meaning the administrative dispute will continue through formal channels. For investors, this development highlights the ongoing necessity for strict operational and regulatory compliance in the pharmaceutical sector. This local regulatory focus comes alongside broader monitoring of the company's manufacturing footprint; notably, Cipla also received seven observations from a USFDA inspection at its Pithampur facility in August 2026.
The primary monitorable for investors will be the company’s management of the fresh show cause notice process with the Maharashtra FDA. Since the court has emphasized the need for due process, the upcoming administrative interactions will determine the final standing of the Pune facility’s license. Beyond this specific local case, the broader context of how the company addresses regulatory observations—both at its distribution hubs and its large-scale manufacturing units—will be a key factor in assessing operational stability.